SNSS News and Press, Viracta Therapeutics Inc Com From 05/08/19

Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter e...

SOUTH SAN FRANCISCO, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter end...

SOUTH SAN FRANCISCO, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank . The new agreement allows the company to retire its existing loan and defer any pr...

Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% .  SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...

CORAL GABLES, FL / ACCESSWIRE / April 4, 2019 / The success of the healthcare stock market is directly connected to the fact that companies in the healthcare industry are committed to improving the quality of life for consumers in need. According to the most recent global report from the U...

SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18 th A...

LONDON, UK / ACCESSWIRE / March 22, 2019 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first signs of clinical efficacy are expected in the upcoming doses. The drug is being teste...

Sunesis Pharmaceuticals ( SNSS ) Q4 results : Revenues: $0; R&D Expense: $3.3M (-10.8%); SG&A: $2.5M (-10.7%); Net Loss: ($6M) (+9.1%); Loss Per Share: ($0.16) (+23.8%); Quick Assets: $13.7M (-49.3%); CF Ops: ($24.4M) (+32.4%). More news on: Sunesis Pharmaceuticals, Inc., Healthca...

Sunesis Pharmaceuticals, Inc. (SNSS) Q4 2018 Earnings Conference Call March 07, 2019 04:30 PM ET Company Participants Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scien...

Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q4 GAAP EPS of -$0.16 beats by $0.03 . More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...